San Diego biotech raises $90 million to treat infections in people with weak immune systems
SAN DIEGO — San Diego biotech company Amplyx Pharmaceuticals announced Tuesday that it has completed a $53 million extension to its Series C funding round, bringing the total for the round to $90 million.Sofinnova Venture Partners led the round, with participation from more than seven investment firms that had contributed in earlier rounds. Pfizer and Adage Capital Management joined the mix as new investors.The funds will mainly go toward testing two experimental drugs central to Amplyx’s mission — treating microbes that are usually harmless, but which can kill a person without a healthy immun...
The San Diego Union-Tribune
Lee Schafer: There's still resilience in tech startups in middle of the US
MINNEAPOLIS — One of the most optimistic reports in years about the venture capital available for startup companies in our region appeared this week, in the middle of a pandemic when it’s hard to feel great about anything.It is a good news story, though, even if more venture capital may not be the perfect measure of the health of a region’s entrepreneurial community. More beats less, no matter the economic environment.And the report’s details jump out for what they show about entrepreneurship here: that middle-of-the-country entrepreneurs seem to get more work done with less money.It might be ...
Star Tribune (Minneapolis)